Fourth quarter and full year 2023 results
Fourth quarter and full year 2023 results were reviewed by management during a live audio webcast with the financial community on February 1st, 2024. The presentation was followed by a Q&A session.
14:30 - 16:00 CET (8:30am – 10am EST)
Featuring
Paul Hudson
Chief Executive Officer
Jean-Baptiste de Chatillon
Chief Financial Officer
Brian Foard
Specialty Care
Olivier Charmeil
General Medicines
Houman Ashrafian
R&D
Thomas Triomphe
Vaccines
Julie van Ongevalle
Consumer Healthcare
Roy Papatheodorou
General Counsel
Highlights
Paul Hudson comments on 2023 results
Full-Year 2023 results and R&D highlights
2023 was a turning-point year for Sanofi, paving the way for our scientific leadership in Immunology. Coupled with our AI at-scale ambitions, we go forward as a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth.
Paul Hudson
Chief Executive Officer